Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01461837 · ClinicalTrials.gov registry record · Phase 2
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by New York Medical College.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 6
- Study locations
NCT01461837: Active Phase 2 study of Sickle Cell Disease, sponsored by New York Medical College.
NCT01461837 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by New York Medical College. The registered enrollment target is 21 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01461837, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by New York Medical College.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients. Funding Source - FDA OOPD
Primary Outcome
Death, primary or late graft rejection, or recurrence of disease and acceptable rate of hematopoietic engraftment, acute and chronic graft-versus-host disease
Conditions Studied
Interventions
- DRUG CD34 selected T-cell depleted allogeneic SCT
Study Locations (6)
California
- University of California Los Angeles (UCLA) - Los Angeles
- Children's Hospital and Research Center Oakland - Oakland
Illinois
- Lurie Children's Hospital - Chicago
Missouri
- Washington University/St. Louis Children's Hospital - St Louis
New York
- New York Medical College - Valhalla
Wisconsin
- Medical College of Wisconsin/Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT01461837 still lists
NCT01461837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which CD34 selected T-cell depleted allogeneic SCT is the first listed.
NCT01461837 lists 6 locations in 5 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT01461837 about?
NCT01461837 is a clinical study titled "Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease". This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk si...
What is the current status of trial NCT01461837?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2012-01. Estimated completion is 2026-12.
What conditions does trial NCT01461837 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT01461837?
The interventions under investigation include: CD34 selected T-cell depleted allogeneic SCT (DRUG).
Who is sponsoring clinical trial NCT01461837?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01461837 being conducted?
This trial has 6 study locations across California, Illinois, Missouri, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01461837's enrollment target sits among peer trials
21 169th of 213 higher than 43 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
- NCT04401605 · 21 participants · NA
Fermented Food-Supplemented Diet in Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia